SLCO1B3 Antibody, HRP conjugated

說明書

中文名稱：

SLCO1B3兔多克隆抗體, HRP偶聯
貨號：

CSB-PA882065LB01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) SLCO1B3 Polyclonal antibody
Uniprot No.：

Q9NPD5
基因名：

SLCO1B3
別名：

HBLRR antibody; Liver-specific organic anion transporter 2 antibody; LST-2 antibody; LST-3TM13 antibody; LST3 antibody; OATP-8 antibody; OATP1B3 antibody; Organic anion transporter 8 antibody; Organic anion-transporting polypeptide 8 antibody; SLC21A8 antibody; SLCO1B3 antibody; SO1B3_HUMAN antibody; Solute carrier family 21 member 8 antibody; Solute carrier organic anion transporter family member 1B3 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Solute carrier organic anion transporter family member 1B3 protein (648-695AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
基因功能參考文獻：
1. Organic anion-transporting polypeptide 1B3 as a dual reporter gene for fluorescence and magnetic resonance imaging. PMID: 29146731
2. When including the expression levels of SLCO1B3 in intraoperatively examined lymph nodes, 8 factors were found able to predict the prognosis of patients with carcinomas of the cecum and ascending colon. As regards the surgical therapeutic strategies, the resection of >15 local lymph nodes is appropriate for improving the prognosis of patients. PMID: 29658575
3. Ct-OATP1B3 mRNA exists in extracellular vesicles and can be detected in (at least) mouse serum, strengthen the potential use of Ct-OATP1B3 mRNA as a serum-based Colorectal Cancer biomarker PMID: 29491222
4. It shows high expression of OATP1B3 mRNA in human pancreatic islets, and a high association of OATP1B3 immunostaining with glucagon-producing pancreatic alpha cells. PMID: 28815335
5. This study suggests that de novo OATP1B3 expression in prostate cancer drives greater androgen uptake and is consistent with previous observations that greater OATP1B3 activity results in the development of androgen deprivation therapy resistance and shorter overall survival PMID: 28389619
6. rs4149117 had no association with hypoglycaemia. The rs4149117 mutation in the SLCO1B3 gene is not associated with sulfonylurea efficacy. PMID: 28444661
7. Patients homozygous for the variant allele had significantly higher average E1C plasma concentrations than did other patients. Furthermore, three other SLCO1B1 SNPs, not in LD with rs4149056, were associated with both E1C concentrations and the E1C/E1 ratio and were cis-eQTLs for SLCO1B3. PMID: 28429243
8. OATP1B3 protein expression starts at a very high expression level throughout the neonatal phase, thereafter declining in the early childhood years. Then protein expression starts to increase again during the preadolescent period. PMID: 27098745
9. High transcript levels of OATP1B3, but not OATP1B1 were observed in isolated human adult islets. While OATP1B3 protein expression was variable, the carrier co-localized more frequently with glucagon-positive alpha cells than insulin-positive beta cells in islets of normal pancreatic tissues from ten subjects using dual immunostaining. PMID: 28493059
10. the current studies for the first time report ubiquitination of OATP1B1 and OATP1B3 and the apparent substrate-dependent inhibitory effect of bortezomib on OATP1B3-mediated transport. The data suggest that bortezomib has a low risk of causing OATP-mediated DDIs PMID: 29107984
11. Study showed that the multi-specific liver transporter OATP1B3 can form homo-oligomers and can interact with other transporters in the liver, including OATP1B1 and NTCP. We also demonstrated that the homo-oligomers work as two or more individual functional subunits. PMID: 28644885
12. demonstrate that the N-terminal region is important for the membrane localization of the OATP1B subfamily members and should facilitate future investigations of the mechanisms involved in the regulation and membrane trafficking of these important transporter proteins PMID: 28216016
13. SLCO1B3 was significantly downregulated in docetaxel-resistant patient-derived prostatic tumours xenografted into mice. SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxel and consequently influences taxane efficacy. Loss of the drug transporter SLCO1B3 may drive taxane resistance in prostate cancer. PMID: 27537383
14. Our results indicated that OATP1B3 may play an important role in the transport of glycocholic acid and glycochenodeoxycholic acid in the human placenta. PMID: 25345542
15. Cancer-type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives PMID: 26264344
16. Carriers of a T allele of SLCO1B3-rs4149117 were less sensitive to thrombocytopenia than the homozygotes for the G allele PMID: 26267044
17. Data suggest that OATP1B3 facilitates transport of the shellfish toxin okadaic acid into hepatocytes. PMID: 26134461
18. SLCO1B3 699GG and 344TT genotypes are associated with non-response to IM, while ABCA3 4548-91 CC/CA genotypes are related to poor CMR in CML patients treated with standard-dose imatinib. PMID: 25056761
19. OATP1B3 was confirmed as the most important transporter mediating hepatocellular carcinoma enhancement in gadoxetic acid-enhanced magnetic resonance imaging. PMID: 24946283
20. studies elucidate a novel indirect inhibitory mechanism affecting hepatic uptake mediated by OATP1B3, and provide new insights into predicting OATP-mediated drug interactions between OATP substrates and kinase modulator drugs/endogenous compounds PMID: 25200870
21. expression elevated in indocyanine green-accumulated hepatocellular carcinoma PMID: 25173835
22. HEK293-OATP1B3 cells are resistant to microcystin-LR induced anoikis. PMID: 25456266
23. Report regulation of OATP1B3-mediated telmisartan uptake in cultured hepatocytes. PMID: 24628404
24. SLCO1B3 expression and promoter activity are modulated by COL7A1 in tumor keratinocytes isolated from recessive dystrophic epidermolysis bullosa. PMID: 24357722
25. Cancer-type - OATP1B3 is capable of transporting its substrates into cancer cells. Its mRNA expression is regulated by DNA methylation-dependent gene silencing involving MBD2. PMID: 23812637
26. CYP3A5*3 polymorphism was associated with imatinib efficacy while the SNP SLCO1B3 (T334G) was not associated with the response to imatinib treatment in Egyptian patients with CML in chronic phase. PMID: 23394475
27. These data provide evidence that the drug transporter OATP1B3 functions as a determinant of the insulinotropic effect of glibenclamide on the tissue level. PMID: 24150606
28. The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer disease-free survival. PMID: 23782748
29. The transcription of cancer-specific OATP1B3 is regulated during hypoxia through a commonly utilized pathway involving HIF-1alpha. PMID: 23924606
30. Colon and pancreatic cancer cells express variant forms of OATP1B3. PMID: 23215050
31. Data indicate that SLCO1B3 knockdown reduced cell size and 3-dimensional spheroid volume. PMID: 23352438
32. There was no significant association of the SLCO1B3 polymorphisms with docetaxel clearance or neutropenia. PMID: 23188068
33. The presence of the rs2117032 polymorphism of SLCO1B3 seemed to provide protection from hyperbilirubinemia. PMID: 22580719
34. The expression of OATP1A2 and OATP1B3 in placenta decreased in, and may be involved in the pathophysiology of, intrahepatic cholestasis of pregnancy. OATP1B3 was localized to the vasculo-syncytial membrane of syncytiotrophoblasts. PMID: 22203093
35. Site-directed mutagenesis of three key residues in OATP1B1 transmembrane helices 1 and 10, and extracellular loop 6, to the corresponding residues in OATP1B3, resulted in a gain of CCK-8 transport by OATP1B1. PMID: 22352740
36. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients PMID: 21995462
37. Thirty-six variations of OATP1B3 were identified in the Korean population, consisting of nine variations in the 5'-upstream region, ten in the exon regions, and seventeen in the intron regions. PMID: 22147445
38. Isoform specific mRNA quantification showed that the Ct-OATP1B3 mRNA level was strikingly higher than that of Lt-OATP1B3 mRNA in human cancer tissues. PMID: 22326869
39. immunohistochemical expression of OATP8 significantly decreases during multistep hepatocarcinogenesis PMID: 21626360
40. SLCO1B3 expression, rather than CTNNB1 mutation, is the critical determinant of intratumoral cholestasis. PMID: 21615622
41. Genetic variants of SLCO1B3 may function as pharmacogenomic determinants of resistance to androgen deprivation therapy in prostate cancer. PMID: 21606417
42. Data indicate that hydroxyurea transport and cellular uptake by OATP1B3 is time- and temperature-dependent. PMID: 21256917
43. OATP1B3 polymorphisms that result in altered expression, substrate specificity, and pH-dependent activity may be of potential relevance to hepatic clearance of substrate drugs in vivo. PMID: 21278621
44. These results suggested that the SLCO1B3 334T>G polymorphism could have a significant impact on the intracellular concentration of imatinib in leukocytes as a promising biomarker for personalized treatment of chronic myeloid leukemia patients. PMID: 21212528
45. Forty one nucleotide sequence variants leading to nine major haplotypes in the SLCO1B3 were identified in caucasian Canadians. PMID: 20877131
46. Genetic variations of SLCO1B3 and UGT1A1 is associated serum bilirubin levels in Korean population. PMID: 20639394
47. SLCO1B3 polymorphism significantly influences plasma mycophenolic acid glucuronide pharmacokinetics in Japanese renal transplant recipients. PMID: 18695635
48. OATP1B3 is one of the transporters contributing to the supply of the estrogen precursor estrone-3-sulfate to estrogen-dependent breast cancer cells. PMID: 20615467
49. DNA methylation-dependent gene silencing is at least partly involved in the regulation of OATP1B3 expression in cancer/immortalized cell lines. PMID: 20130966
50. In this review, organic anion transporting polypeptide (OATP)1B3 is an uptake transporter specifically expressed in the liver, and is considered important for drugs, particularly as its pharmacological target organ is the liver. PMID: 19442037
顯示更多

收起更多
相關疾病：

Hyperbilirubinemia, Rotor type (HBLRR)
亞細胞定位：

Basolateral cell membrane; Multi-pass membrane protein.
蛋白家族：

Organo anion transporter (TC 2.A.60) family
組織特異性：

Highly expressed in liver, in particular at the basolateral membrane of hepatocytes near the central vein. Not detected in other tissues. Highly expressed in some cancer cell lines derived from colon, pancreas, liver and gall bladder.
數據庫鏈接：

HGNC: 10961

OMIM: 237450

KEGG: hsa:28234

STRING: 9606.ENSP00000261196

UniGene: Hs.504966

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat